EPRX EUPRAXIA PHARMACEUTICALS INC.

NEUTRAL Impact: 2/10 6-K
Horizon days Filed May 28, 2026 Processed 17d 14h ago SEC 0001171843-26-003762
Notable filing: 6-K
Latest settled — T+5d ⚠ clustered
EPRX ▼ -16.08% at T+5d
NEUTRAL call ✗ call lost -16.08% · α vs SPY -13.56% · entry $7.09 → $5.95
Next anchor: T+20d in 11d
Last close $6.04 (close Jun 12) · -14.81% from $7.09 entry
Entry anchored
May 28, 2026
via day open
T+1d
-3.24%
call -3.24% · α -3.50%
$6.86
settled 17d ago
T+5d
-16.08%
call -16.08% · α -13.56%
$5.95
settled 11d ago
T+20d
call — · α —
in 11d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Eupraxia Pharmaceuticals filed a 6-K announcing management's participation in the Jefferies Global Healthcare Conference on June 3-4, 2026. The filing contains no new clinical data, financial results, or material corporate developments — it is a routine investor conference announcement.

Actionable Insight

This is a routine conference participation announcement with no material news. Monitor the conference webcast on June 3 for any pipeline updates or commentary, but no immediate trading catalyst is present.

Key Facts

  • Eupraxia management will present at the Jefferies Global Healthcare Conference on June 3, 2026, from 5:30-6:00 PM ET.
  • 1x1 investor meetings are scheduled for June 3 and 4, 2026.
  • The filing includes no new clinical data, financial guidance, or material business updates.
  • The company is a clinical-stage biotech with EP-104GI in Phase 1b/2 (RESOLVE trial for EoE) and a completed Phase 2b (SPRINGBOARD) for knee osteoarthritis pain.

Financial Impact

No financial figures disclosed in the filing.

Risk Factors

  • No new clinical data or financial updates — stock may drift on sector sentiment.
  • Conference participation alone rarely moves stock price without accompanying data or guidance.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-003762
Exhibit: exh_991.htm0001171843-26-003762
Document: 0001171843-26-003762-index-headers.html0001171843-26-003762
Document: 0001171843-26-003762-index.html0001171843-26-003762
Document: 0001171843-26-003762.txt0001171843-26-003762
8 reports for EPRX
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+5▲ +16.69%May 12, 2026
Filters
Rows
Reports for EPRX — sortable, filterable
Type Now
May 29, 2026
16d ago
6-K
NEUTRAL ★ 3/10
$7.09 $6.33▼ −10.72%▼ −10.43%$6.04 (−14.81%)
May 29, 2026
16d ago
6-K
NEUTRAL ★ 2/10
$7.09 $6.33▼ −10.72%▼ −10.43%$6.04 (−14.81%)
May 28, 2026
17d ago
6-K
NEUTRAL ★ 2/10
$7.09 $5.95▼ −16.08%▼ −13.56%$6.04 (−14.81%)
May 12, 2026
4w ago
Press Release
BEARISH ★ 7/10
$7.55 $6.29▲ +16.69%▲ +15.53%$6.04 (+20.00%)
Apr 22, 2026
7w ago
6-K
NEUTRAL ★ 4/10
$7.06 $7.11▲ +0.71%▲ +0.65%$6.04 (−14.45%)
Apr 21, 2026
7w ago
6-K
BULLISH ★ 7/10
$7.02 $7.11▲ +1.28%▲ +0.20%$6.04 (−13.96%)
Apr 21, 2026
7w ago
Press Release
BULLISH ★ 8/10
$7.02 $7.11▲ +1.28%▲ +0.20%$6.04 (−13.96%)
Mar 13, 2026
13w ago
Press Release
MIXED ★ 6/10
$7.36 $7.10▼ −3.53%▼ −1.41%$6.04 (−17.93%)
Showing 8 of 8

US Market Status

Market Closed — Opens in 2h 54m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access